Abstract:Clinical studies have shown that pre-existing tumor-reactive T cells are critically important for effective cancer immunotherapy. Methods to augment the number and functionality of tumor-reactive T cells are therefore vital. Given that cytotoxic CD8 T cell priming requires conventional dendritic cells (cDC), we hypothesized that strategies to enhance cDC functionality in tumors would augment anti-tumor CD8 T cell responses. CD40 and type 1 IFN signaling pathways each promote the cross-presentation function of cDCs to activate CD8 T cells. However, it is unclear whether these pathways are functionally independent and whether their combined activation in tumor cDC leads to higher levels of T cell priming. Using adenovirus vectors, we tested the impact of expression of IFNβ and a chimeric membrane-stable CD40 ligand (MEM40) in syngeneic mouse tumor models. Compared to intratumoral administration of each individual transgene-encoding adenovirus, combined MEM40 + IFNβ expression resulted in the best tumor growth control, highest levels of tumor infiltrating lymphocytes (TILs), and systemic CD8 T cell responses. MEM40 and IFNβ were independently capable of enhancing T cell responses as we found IFNβ in CD40-/- mice and MEM40 in type 1 IFN receptor IFNAR1-/- mice induced a strong T cell response. These results were consistent with a cDC-mediated priming mechanism. Studies with cDC1 deficient BATF3-/- mice revealed a crucial role of this cDC subset in MEM40 + IFNβ induced T cell responses. IFNβ alone and MEM40 + IFNβ triggered increase in lymph node (LN) homing receptor CCR7 expression in cDC1 concurrent with a reduction in cDC1 in tumors and gain in tumor draining LNs. Simultaneously, combined MEM40 + IFNβ combination led to the highest levels of expression of CD80 and CD86 co-stimulatory molecules in both tumor and LN cDC1. Single cell (sc)-RNA sequencing of tumor DCs further showed that MEM40 + IFNβ led to the highest proportion of a recently defined mature/regulatory cDC subset characterized by high expression of CCR7, CD40 and IL12b. Applying these results towards an effective therapeutic modality, we developed a dual-transgene-armed MEM40 + IFNβ expressing conditionally replicative adenovirus (MEM-288) that simultaneously confers tumor-specific oncolysis and promotes tumor antigen release. MEM-288 drives MEM40 + IFNβ expression in freshly resected human lung tumors and generates potent anti-tumor responses as a monotherapy and in combination with immune checkpoint inhibitors. Furthermore, MEM-288 induced enhancement of tumor-reactive TILs and provides a rationale for studies to determine whether MEM-288 pre-treatment generates a superior TIL product for more effective adoptive T cell therapy. Citation Format: Hong Zheng, Scott Antonia, Mark J. Cantwell, Xiaoqing Yu, Amer A. Beg. Oncolytic adenovirus encoding transgenes for IFN-beta and recombinant CD40 ligand promotes conventional dendritic cell activation and trafficking with enhanced tumor infiltrating lymphocytes for effective cancer immunotherapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl) nr 3542.

CD40 Agonist Converting CTL Exhaustion Via the Activation of the Mtorc1 Pathway Enhances PD-1 Antagonist Action in Rescuing Exhausted CTLs in Chronic Infection.

Novel Exosome-Targeted T-Cell-Based Vaccine Counteracts T-Cell Anergy and Converts Ctl Exhaustion in Chronic Infection Via Cd40l Signaling Through the Mtorc1 Pathway

mTOR signals regulate T cell exhaustion and T cell responses during PD-1 targeted immunotherapy in chronic viral infection.

Restoring function in exhausted CD8 T cells during chronic viral infection

Epigenetic tuning of PD-1 expression improves exhausted T cell function and viral control

Regulation of Human Immunodeficiency Virus Type 1 Infection, Β-Chemokine Production, and CCR5 Expression in CD40L-Stimulated Macrophages: Immune Control of Viral Entry

Chronic viral infection alters PD-1 locus subnuclear localization in cytotoxic CD8+ T cells

PD-1 combination therapy with IL-2 modifies CD8 + T cell exhaustion program

Reversal of the CD8+ T-Cell Exhaustion Induced by Chronic HIV-1 Infection Through Combined Blockade of the Adenosine and PD-1 Pathways

A CD64/FcγRI-mediated mechanism hijacks PD-1 from PD-L1/2 interaction and enhances anti-PD-1 functional recovery of exhausted T cells

PD-1 and CTLA-4 serve as major gatekeepers for effector and cytotoxic T-cell potentiation by limiting a CXCL9/10-CXCR3-IFNγ positive feedback loop

PD-1 knockout on cytotoxic primary murine CD8+ T cells improves their motility in retrovirus infected mice

TGF-β regulates the stem-like state of PD-1+ TCF-1+ virus-specific CD8 T cells during chronic infection

Dynamic CD4+ T cell heterogeneity defines subset-specific suppression and PD-L1-blockade-driven functional restoration in chronic infection

CXCL10-armed oncolytic adenovirus promotes tumor-infiltrating T-cell chemotaxis to enhance anti-PD-1 therapy

Indirect Impact of PD-1/PD-L1 Blockade on a Murine Model of NK Cell Exhaustion

Cd154 And Il-2 Signaling Of Cd4(+) T Cells Play A Critical Role In Multiple Phases Of Cd8(+) Ctl Responses Following Adenovirus Vaccination

CD40 stimulation activates CD8+ T cells and controls HBV in CD4-depleted mice

PD-1 immune checkpoint blockade can synergize with PSGL-1 inhibition to reinvigorate exhausted T cells

The Transcription Factor TCF1 Preserves the Effector Function of Exhausted CD8 T Cells During Chronic Viral Infection

Abstract 3542: Oncolytic adenovirus encoding transgenes for IFN-beta and recombinant CD40 ligand promotes conventional dendritic cell activation and trafficking with enhanced tumor infiltrating lymphocytes for effective cancer immunotherapy